Research
Hormonal
Higher levels of physical activity reduce the risk of six specific cancer sites (bladder, breast, colon, endometrial, esophageal adenocarcinoma, gastric cardia) with strong evidence, while moderate evidence supports inverse associations with lung, ovarian, pancreatic, and renal cancers.
Aim for regular physical activity to lower cancer risk. You do not need a specific dose to start; even breaking up long periods of sitting with standing or walking offers benefits. Consistency matters more than intensity for general risk reduction.
StrongSupportsHIGH confidence
Strong and consistent evidence exists that higher levels of physical activity reduce the risk of six different cancer sites (bladder, breast, colon, endometrial, esophageal adenocarcinoma, gastric cardia), whereas moderate evidence inversely associates physical activity with lung, ovarian, pancreatic and renal cancer...
Why this rating
Classified as 'Strong' and 'Moderate' evidence by major guidelines (PAGA, WCRF/AICR).
Source
Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms
Christine M. Friedenreich et al. · Molecular Oncology · 2020
DOI 10.1002/1878-0261.12772
narrative_reviewCited 653×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity (excess body fatness) is a convincing risk factor for at least 13 different cancer sites, including endometrial, postmenopausal breast, colorectal, esophageal, renal, meningioma, pancreatic, gastric cardia, liver, multiple myeloma, ovarian, gallbladder, and thyroid cancers.Strong
- High levels of sedentary behavior independently increase the risk of colon, endometrial, and lung cancers, regardless of physical activity levels.Good
- Biologic mechanisms linking physical activity, sedentary behavior, and obesity to cancer risk include effects on endogenous insulin sensitivity, chronic sex steroids, metabolic hormones, and inflammation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →